KalVista Pharmaceuticals (NASDAQ:KALV) CFO Brian Piekos Sells 1,489 Shares

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CFO Brian Piekos sold 1,489 shares of the firm’s stock in a transaction on Friday, May 22nd. The shares were sold at an average price of $26.78, for a total transaction of $39,875.42. Following the completion of the transaction, the chief financial officer directly owned 21,661 shares of the company’s stock, valued at approximately $580,081.58. The trade was a 6.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Brian Piekos also recently made the following trade(s):

• On Friday, April 17th, Brian Piekos sold 1,862 shares of KalVista Pharmaceuticals stock. The shares were sold at an average price of $20.22, for a total transaction of $37,649.64.

KalVista Pharmaceuticals Price Performance

NASDAQ:KALV traded up $0.02 during trading hours on Tuesday, hitting $26.81. The stock had a trading volume of 8,068,030 shares, compared to its average volume of 7,414,539. The company has a 50 day simple moving average of $21.74 and a two-hundred day simple moving average of $17.54. The company has a debt-to-equity ratio of 8.18, a current ratio of 5.17 and a quick ratio of 5.10. KalVista Pharmaceuticals, Inc. has a one year low of $9.83 and a one year high of $26.85. The firm has a market capitalization of $1.43 billion, a price-to-earnings ratio of -7.75 and a beta of -0.12.

KalVista Pharmaceuticals (NASDAQ:KALV) last posted its quarterly earnings data on Thursday, May 14th. The specialty pharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). The firm had revenue of $39.17 million for the quarter, compared to the consensus estimate of $39.03 million. Research analysts forecast that KalVista Pharmaceuticals, Inc. will post -0.96 earnings per share for the current fiscal year.

Hedge Funds Weigh In On KalVista Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the stock. Bank of America Corp DE raised its stake in KalVista Pharmaceuticals by 42.5% in the first quarter. Bank of America Corp DE now owns 555,628 shares of the specialty pharmaceutical company’s stock worth $11,185,000 after buying an additional 165,815 shares in the last quarter. Royal Bank of Canada raised its stake in KalVista Pharmaceuticals by 137.0% in the first quarter. Royal Bank of Canada now owns 2,917 shares of the specialty pharmaceutical company’s stock worth $59,000 after buying an additional 1,686 shares in the last quarter. Elmind Capital LP raised its stake in KalVista Pharmaceuticals by 27.5% in the first quarter. Elmind Capital LP now owns 1,021,300 shares of the specialty pharmaceutical company’s stock worth $20,559,000 after buying an additional 220,000 shares in the last quarter. Quantinno Capital Management LP increased its stake in shares of KalVista Pharmaceuticals by 11.3% during the first quarter. Quantinno Capital Management LP now owns 32,453 shares of the specialty pharmaceutical company’s stock valued at $653,000 after purchasing an additional 3,297 shares in the last quarter. Finally, Octagon Capital Advisors LP increased its stake in shares of KalVista Pharmaceuticals by 13.9% during the first quarter. Octagon Capital Advisors LP now owns 1,450,000 shares of the specialty pharmaceutical company’s stock valued at $29,188,000 after purchasing an additional 176,667 shares in the last quarter.

Analyst Ratings Changes

Several equities research analysts recently weighed in on KALV shares. Leerink Partners cut KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, April 29th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 21st. Wall Street Zen downgraded shares of KalVista Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, April 21st. Citizens Jmp downgraded shares of KalVista Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, April 29th. Finally, HC Wainwright downgraded shares of KalVista Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price objective for the company from $37.00 to $27.00 in a research note on Friday, May 1st. Three research analysts have rated the stock with a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $30.60.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals is a clinical‐stage biotechnology company focused on the discovery and development of small‐molecule protease inhibitors for orphan and specialty disease indications. The firm’s scientific platform centers on selective inhibition of plasma kallikrein, a serine protease implicated in disorders characterized by vascular leak, edema and inflammation. KalVista’s approach leverages oral and intravitreal delivery formats to target both systemic and ophthalmic conditions.

The company’s lead programs include an oral plasma kallikrein inhibitor in clinical trials for the acute treatment of hereditary angioedema (HAE) attacks and an intravitreal kallikrein inhibitor being evaluated for diabetic macular edema.